# Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia

> **NCT00030355** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** homoharringtonine
- **PROCEDURE:** chemotherapy

## Key facts

- **NCT ID:** NCT00030355
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2013-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00030355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00030355, "Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00030355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*